BioCryst Increases Wholesale Acquisition Cost for Key Drug ORLADEYO® by 9%
Summary
BioCryst Pharmaceuticals has raised the wholesale acquisition cost for its HAE drug, ORLADEYO®, by approximately 9%, effective January 9, 2026, which is expected to boost future revenue.
Key Events
-
ORLADEYO® Price Increase
BioCryst Pharmaceuticals has increased the wholesale acquisition cost (WAC) for its drug ORLADEYO® from $44,484.33 to $48,487.92 per 28-day pack in the U.S.
-
Significant Revenue Impact
The price adjustment represents an approximate 9% increase, which is expected to positively impact the company's future revenue and gross profit for this key product.
-
Immediate Effect
The new pricing for ORLADEYO® is effective as of January 9, 2026.
Analysis
BioCryst Pharmaceuticals announced a 9% increase in the wholesale acquisition cost (WAC) for its hereditary angioedema (HAE) drug, ORLADEYO®. This price adjustment, effective immediately, is expected to positively impact the company's revenue and gross profit margins. For a commercial-stage biopharmaceutical company, a direct price increase on a flagship product can significantly enhance financial performance and accelerate the path to profitability, demonstrating strong pricing power for a specialized treatment.
At the time of this filing, BCRX was trading at $7.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $6.00 to $11.31. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.